Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- EFPIA and PhRMA Announce Joint “Principles for Responsible Clinical Trial Data Sharing”
July 26, 2013
- SCJ to Discuss Preventive Measures for Misconduct in Science Research
July 24, 2013
- NPO J-CLEAR Says Diovan Data Manipulated Possibly Outside of Endpoint Committee
July 24, 2013
- JPMA Calls on TPP Member States to Make Drug Pricing Process Transparent
July 22, 2013
- FPMAJ Settles on Industry View for TPP, Demands Intellectual Property Protection on Par with Japanese Rules
July 19, 2013
- JPWA Sets Up New Committee on Consumption Tax, NHI Drug Pricing Issues
July 12, 2013
- Pharmaceutical-Related Companies Should Report Business Results to CSIMC: JMARI Working Paper
July 11, 2013
- Product Names Changed for 10% of New Drugs after NDA Filings: OPIR Survey
July 8, 2013
- JSGM Officially Announces Unified Brand Name Plan for Generic Combination Drugs; 1st Single Name to Be Given to Preminent
July 8, 2013
- JSGM Working to Build Consensus on Unified Brand Names for Generic Combination Drugs
July 5, 2013
- JPA to Bolster Strategies for Key Issues thru Policy Study Committee: Pres. Kodama
July 2, 2013
- JMA Sets Up Pharmaceutical Affairs Section
July 1, 2013
- Generic Share Reaches 25.8% by Volume, 10.5% by Price in FY2012: JGA
July 1, 2013
- JGA to Establish New Membership Category to Encourage Non-Member Companies to Provide Information through Its Website
June 27, 2013
- JGA Concerned about TPP Talks, Hopes Japan Will Adopt US Rules Favorable to Generic Makers
June 24, 2013
- JPMA Weighs Scheme to Allow Use of Clinical Research Evidence for Drug Applications
June 21, 2013
- Generic-Only Distributors Total 485, Only 17% Are Member Companies: Generic Distributor Association Survey
June 13, 2013
- FPMAJ Subcommittee Floats New Pricing Rule to Replace Cost Calculation Method
June 12, 2013
- FPMAJ Subcommittee Says NHI Prices of Essential Drugs Should Be Maintained; Stable Supply System for Disasters Envisioned as Requirement
June 11, 2013
- 30% of Newly Listed Drugs in FY2012 Developed at Request of Govt: FPMAJ Survey
June 10, 2013
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…